PEA (Test)

La Palmitoiletanolamida (PEA) es una amida de ácido graso omega 7 endógena (producida en el cuerpo) y es un compuesto cannabimimético con propiedades únicas.

Quick facts

  • PEA is an effective and well-tolerated alternative for the treatment of chronic pain

¿PARA QUÉ SIRVE EL PEA?

El PEA es conocido por su capacidad para reducir el dolor crónico y neuropático al modular la respuesta inflamatoria y actuar sobre el sistema endocannabinoide.

Tipos de dolor que el PEA ayuda a manejar:

  • Dolores inflamatorios: artritis, artrosis, dolor menstrual, dolor abdominal y pélvico típico de la endometriosis, enfermedad inflamatoria intestinal o esclerosis múltiple.
  • Dolores neuropáticos: neuropatía diabética, neuropatía post tratamientos quimioterápicos, lumbalgias, ciática o neuralgias post herpéticas.
  • Dolores mixtos (inflamatorios + neuropáticos): síndrome del intestino irritable, fibromialgia, síndrome de fatiga crónica, polimialgia reumática.

SABÍAS QUÉ...

De manera prácticamente universal todas las personas pueden tomar ZeroDol. No hay ninguna condición, enfermedad o medicación prescrita, que contraindique el uso del ácido graso omega 7 PEA.

Clinical Studies

PEA: Natural pain reliever for everyone

A recent meta-analysis of 11 randomized controlled trials on the effectiveness of PEA supplementation in participants suffering from chronic pain due to a variety of conditions including spinal cord injury, endometriosis, irritable bowel syndrome (IBS), carpal tunnel syndrome, temporomandibular joint arthritis (TMJ), vestibulodynia, burning mouth syndrome, diabetic neuropathy, knee osteoarthritis, dysmenorrhea, and regular use of injectable medications for multiple sclerosis showed that PEA may be an effective and well-tolerated treatment for chronic pain.

Read more Read less
Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2023;

The PEA reduces pain intensity

The following study evaluated the effects of PEA on pain modulation in 14 healthy volunteers using a randomized, double-blind, crossover trial. The results showed that PEA reduced induced pain intensity, improved pain tolerance and conditioned pain modulation, with no adverse effects.

Read more Read less
Klivinyi C, Lang-Illievich K, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients. 2022; 4(19):4084.

The PEA in neuropathic pain

This 2022 study evaluated the safety and efficacy of PEA in 70 patients with diabetic neuropathic pain. After 8 weeks of treatment, PEA reduced pain, improved sleep quality, and decreased systemic inflammation without significant adverse effects.

Read more Read less
Pickering, E., Steels, E. L., Steadman, K. J., Rao, A., & Vitetta, L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology, 2023; 30(6), 2063–2077.